Mondelez's 2026 Stock Run and the $77 Fair Value Gap
Mondelez International has been one of the stronger consumer-staples stories of 2026: the stock had gained more than 16% through the August 11 close, even as cost inflation and cautious consumer spending continued to pressure the industry. Yet Morningstar analysts argue the rally has not closed the value gap. The shares were trading roughly 20% below the firm's $77 fair value estimate.
Dave Sekera, Morningstar's chief US market strategist, highlighted Mondelez as a stock to buy in August on The Morning Filter podcast. The company has continued to invest behind its brands while trying to reduce costs through an upgraded enterprise resource planning system, improvements to its global supply chain and cuts to non-consumer-facing media.
Morningstar assigns the company a wide economic moat. The case rests on entrenched retail relationships, strong brand assets and global scale: several brands generate more than $1 billion in annual sales, and about 70% of revenue comes from outside the United States. Management is targeting long-term sales growth of 3%-5% through wider distribution, support for local and global brands, empowered local leadership and faster innovation.
Morningstar's base case assumes about 4% annual organic sales growth and an operating margin that reaches about 18% by the end of its explicit forecast, a gain of more than 100 basis points from the fiscal 2020-24 average. That valuation translates to roughly 16 times expected fiscal 2027 enterprise value to adjusted EBITDA.
How Morningstar's Wide-Moat Math Holds Up for Mondelez
What Makes the Wide Moat More Than a Label
Mondelez's moat is built on retail relationships and brand intangibles rather than a single product. Its scale supports distribution, marketing and procurement advantages, and the company's spending on research, development and marketing is forecast to average around 7% of sales, or about $3bn annually over the next decade. Those resources help maintain shelf space and brand relevance, but they also make the company sensitive to volume and input-cost swings.
Where Morningstar's Upside Assumption Comes From
The profit case leans on three moving parts: organic sales growth near 4%, an expansion of operating margin toward 18%, and continued efficiency gains. Morningstar notes that empowering in-market leaders and increasing investment in local brands should support faster growth in emerging markets. A willingness to prune noncore products could reduce complexity, and lower cocoa costs would be another tailwind for profit beyond fiscal 2026.
The Counterweights: Volume, Cocoa and Health Policy
The main concern is not brand strength but consumer behavior and regulation. Morningstar attributes weakness in North America to value-seeking consumers and lower retail inventory levels. In Europe, volume has fallen by an average of 4% over the past two years following pronounced price increases, and further price rises could prolong the decline. On inputs, cocoa, sugar, dairy and grain costs can fluctuate and pressure margins.
Longer-term demand risks include the wider use of anti-obesity drugs, taxes on less-healthy food, regulation of product formulations and the possibility of a quality issue that requires a recall. These are not signs of immediate distress, but they are the reasons the stock still trades below Morningstar's fair value estimate despite its strong 2026 run.
The Swing Factors Mondelez Investors Can Actually Track
For investors, the core question is whether the stock can close the gap to Morningstar's $77 fair value estimate. Three swing factors are specific enough to track.
- Use the $77 fair value as the reference point. With shares up more than 16% in 2026 but still about 20% below fair value, the remaining upside depends on whether Mondelez delivers the margin and organic-sales assumptions behind that estimate.
- Watch Europe and North America volumes. European volume has declined an average of 4% per year over the past two years, and North America has been held back by value-seeking shoppers and lower retail inventories.
- Track cocoa costs. Morningstar says continued declines in cocoa prices could create profit upside beyond fiscal 2026, while sharp increases in cocoa, sugar, dairy or grain costs would pressure margins.
- Price in health-policy and drug-related risks. Wider use of anti-obesity drugs, taxes on less-healthy food or formulation rules could reduce demand for indulgent snacks, and a recall could disrupt sales.
Risk & Opportunity Assessment
| Commercial Risk | Medium | Input costs for cocoa, sugar, dairy and grains can fluctuate, and European volume has fallen by an average of 4% over the past two years following price increases. |
| Competitive Risk | Medium | Morningstar sees value-seeking consumers shifting toward club and dollar stores, which could favor private-label and lower-priced alternatives over Mondelez's more discretionary snacks. |
| Regulatory Risk | Medium | Governments could tax less-healthy food or regulate product formulations to curb obesity, directly affecting Mondelez's core confectionery and snacking categories. |
| Reputation Risk | Medium | A potential quality issue that requires a recall could undermine consumer trust in brands that generate more than $1 billion in annual sales. |
| Technology Disruption | Medium | Wider use of anti-obesity drugs could reduce global demand for indulgent confectionery and snacking products, a demand-side health innovation rather than an operational technology threat. |
| Commercial Opportunity | High | Morningstar sees margin gains toward 18%, faster emerging-market growth from local brand investment, possible pruning of noncore products and lower cocoa costs as potential profit tailwinds. |
Comments 0